Myron Karon

2.8k total citations
51 papers, 2.3k citations indexed

About

Myron Karon is a scholar working on Molecular Biology, Pediatrics, Perinatology and Child Health and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Myron Karon has authored 51 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 13 papers in Pediatrics, Perinatology and Child Health and 11 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Myron Karon's work include Childhood Cancer Survivors' Quality of Life (8 papers), DNA and Nucleic Acid Chemistry (8 papers) and Acute Lymphoblastic Leukemia research (8 papers). Myron Karon is often cited by papers focused on Childhood Cancer Survivors' Quality of Life (8 papers), DNA and Nucleic Acid Chemistry (8 papers) and Acute Lymphoblastic Leukemia research (8 papers). Myron Karon collaborates with scholars based in United States, Spain and Canada. Myron Karon's co-authors include Richard L. Momparler, Stuart E. Siegel, Sherman M. Weissman, John J. Spinetta, David Rigler, William F. Benedict, Denman Hammond, Emil J. Freireich, Robert E. Hittle and Mark E. Nesbit and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Myron Karon

50 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Myron Karon United States 27 835 569 495 479 434 51 2.3k
Roger L. Berkow United States 24 801 1.0× 368 0.6× 469 0.9× 325 0.7× 244 0.6× 58 2.5k
W. Lenz Germany 27 875 1.0× 249 0.4× 618 1.2× 142 0.3× 399 0.9× 105 2.9k
Neil J. Clendeninn United States 21 656 0.8× 511 0.9× 223 0.5× 445 0.9× 313 0.7× 45 2.3k
Curt Peterson Sweden 35 1.2k 1.4× 865 1.5× 412 0.8× 1.1k 2.3× 430 1.0× 128 3.5k
Irwin H. Krakoff United States 32 1.5k 1.8× 483 0.8× 362 0.7× 1.7k 3.5× 388 0.9× 124 4.5k
Freidoun Albertioni Sweden 28 696 0.8× 668 1.2× 181 0.4× 440 0.9× 370 0.9× 72 1.9k
Steven Weitman United States 26 1.2k 1.5× 326 0.6× 223 0.5× 880 1.8× 344 0.8× 94 3.1k
Allan J. Jacobs United Kingdom 33 794 1.0× 357 0.6× 229 0.5× 324 0.7× 2.2k 5.0× 135 3.9k
R. Finn United Kingdom 22 413 0.5× 116 0.2× 200 0.4× 231 0.5× 461 1.1× 65 2.2k
Vera S. Byers United States 28 572 0.7× 162 0.3× 114 0.2× 398 0.8× 786 1.8× 80 3.0k

Countries citing papers authored by Myron Karon

Since Specialization
Citations

This map shows the geographic impact of Myron Karon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Myron Karon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Myron Karon more than expected).

Fields of papers citing papers by Myron Karon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Myron Karon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Myron Karon. The network helps show where Myron Karon may publish in the future.

Co-authorship network of co-authors of Myron Karon

This figure shows the co-authorship network connecting the top 25 collaborators of Myron Karon. A scholar is included among the top collaborators of Myron Karon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Myron Karon. Myron Karon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lee, Thomas, Myron Karon, & Richard L. Momparler. (1975). Cellular Phosphorylation of 1-β-d-Arabinofuranosylcytosine and 5-Azacytidine with Intact Fibrosarcoma and Leukemic Cells. Cancer Research. 35(9). 2506–2510. 10 indexed citations
2.
Momparler, Richard L., Joel Goodman, & Myron Karon. (1975). In vitro biochemical and cytotoxicity studies with 1-beta-D-arabinofuranosylcytosine and 5-azacytidine in combination.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 35(10). 2853–7. 6 indexed citations
3.
Nitschke, Ruprecht & Myron Karon. (1975). INHIBITORY EFFECTS OF MITOGENS ON ADENOIDAL LYMPHOCYTES IN VITRO. Cell Proliferation. 8(2). 125–134. 1 indexed citations
4.
Rivard, Georges E., José Antonio Ortega, Robert E. Hittle, Ruprecht Nitschke, & Myron Karon. (1975). Intensive chemotherapy as primary treatment for rhabdomyosarcoma of the pelvis. Cancer. 36(5). 1593–1597. 60 indexed citations
5.
Lee, Thomas, Myron Karon, & Richard L. Momparler. (1974). Kinetic studies on phosphorylation of 5-azacytidine with the purified uridine-cytidine kinase from calf thymus.. PubMed. 34(10). 2482–8. 49 indexed citations
6.
Spinetta, John J., David Rigler, & Myron Karon. (1973). Anxiety in the dying child.. PubMed. 52(6). 841–5. 77 indexed citations
7.
Karon, Myron & William F. Benedict. (1972). Chromatid Breakage: Differential Effect of Inhibitors of DNA Synthesis during G 2 Phase. Science. 178(4056). 62–62. 60 indexed citations
8.
Finklestein, Jerry Z., et al.. (1972). Serum fetoprotein and malignancy in children. Cancer. 30(1). 80–83. 10 indexed citations
9.
Freedman, Melvin H., Jerry Z. Finklestein, G. Denman Hammond, & Myron Karon. (1971). The effect of chemotherapy on acute myelogenous leukemia in children. The Journal of Pediatrics. 78(3). 526–532. 17 indexed citations
10.
Karon, Myron, et al.. (1968). An Approach to the Emotional Support of Fatally Ill Children. Clinical Pediatrics. 7(5). 274–280. 28 indexed citations
11.
Ames, Richard P., J Sobota, Reginald L. Reagan, & Myron Karon. (1966). Virus-Like Particles and Cytopathic Activity in Urine of Patients with Leukemia. Blood. 28(3). 465–478. 11 indexed citations
12.
Karon, Myron, et al.. (1965). STUDIES OF DNA, RNA, AND PROTEIN SYNTHESIS IN CULTURED HUMAN CELLS EXPOSED TO 8-AZAGUANINE.. PubMed. 25. 185–92. 16 indexed citations
13.
Karon, Myron, et al.. (1965). Asymmetrical incorporation of amino acids in the alpha and beta chains of hemoglobin synthesized by thalassemic reticulocytes.. PubMed. 66(3). 476–82. 48 indexed citations
14.
Bodey, Gerald P., Eugene M. McKelvey, & Myron Karon. (1964). Chickenpox in Leukemic Patients— Factors in Prognosis. PEDIATRICS. 34(4). 562–564. 15 indexed citations
15.
Heywood, Joanna, Myron Karon, & Sherman M. Weissman. (1964). Studies of In Vitro Synthesis of Heterogenic Hemoglobins*. Journal of Clinical Investigation. 43(12). 2368–2376. 12 indexed citations
16.
Weissman, Sherman M., et al.. (1964). Studies on the Pseudouridinuria of Chronic Lymphocytic Leukemia. Blood. 24(5). 567–576. 3 indexed citations
17.
Weissman, Sherman M., et al.. (1963). Pseudouridine Metabolism. IV. Excretion of Pseudouridine and Other Nitrogenous Metabolites in Chronic Leukemia. Blood. 22(6). 657–663. 22 indexed citations
18.
Weissman, Sherman M., Arthur Z. Eisen, & Myron Karon. (1962). Pseudouridine metabolism. II. Urinary excretion in gout, psoriasis, leukemia, and heterozygous oroticaciduria.. PubMed. 59. 852–8. 29 indexed citations
19.
Karon, Myron, Emil J. Freireich, & Emil Frei. (1962). A PRELIMINARY REPORT ON VINCRISTINE SULFATE—A NEW ACTIVE AGENT FOR THE TREATMENT OF ACUTE LEUKEMIA. PEDIATRICS. 30(5). 791–796. 47 indexed citations
20.
Eisen, Arthur Z., Sherman M. Weissman, & Myron Karon. (1962). Pseudouridine metabolism. I. Isolation and the effect of diet on urinary excretion.. PubMed. 59. 620–9. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026